Oncology

Top Story

Esophageal cancer in first-degree relative increases Barrett’s risk

Esophageal cancer in first-degree relative increases Barrett’s risk
October 18, 2017

ORLANDO — Patients with Barrett’s esophagus who have a first-degree relative with esophageal adenocarcinoma are at 5.5-fold increased risk for progression to esophageal adenocarcinoma, according to a presenter here.

“Our study suggests that family history of esophageal adenocarcinoma is an independent risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus patients and should be carefully considered in patient surveillance and radiofrequency ablation treatment, beyond current recommended guidelines,” Christina J. Tofani, MD, of Thomas Jefferson University Hospital, said during her presentation.
While it is well-known that esophageal adenocarcinoma is a common complication of Barrett’s esophagus, the significance of family history of esophageal adenocarcinoma in disease progression among patients with Barrett’s esophagus is not well-known.

Meeting News

CHARM: Ethanol-free EUS-guided chemoablation safe, effective

October 18, 2017
ORLANDO — An ethanol-free protocol for pancreatic cyst ablation followed by a combined paclitaxel and gemcitabine regimen for pancreatic neoplasia was effective…
Meeting News

‘Diffusion of responsibility’ leads to missed testing in colon cancer

October 18, 2017
ORLANDO — Though up to 17% of early-onset colon cancers carry genetic markers for Lynch syndrome, only 30% of patients diagnosed with colon cancer younger than age…
Meeting News

Young-onset colon cancers present with physical symptoms, left-side disease

October 18, 2017
ORLANDO — Patients with young-onset colorectal cancer commonly presented with physical symptoms such as rectal bleeding, pain and bloating and nearly 70%…
More Headlines »
CME CNE CPE

Familial Chylomicronemia Syndrome: Cause, Effect, and Solutions to Improve Patients' Quality-of-Life

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Pancreas Foundation.

Familial chylomicronemia syndrome (FCS) is a rare and potentially life-threatening genetic disease. The clinical…
More »
GI Bookshelf

Chapter 5: Dysplasia And Colorectal Cancer

From Clinical Challenges and Complications of IBD
More »
Resource Centers
American College of Gastroenterology Annual Meeting

American College of Gastroenterology Annual Meeting

Video
Meeting News Coverage

VIDEO: ‘Great promise’ in genetic markers for identifying malignancy in pancreatic cysts

June 7, 2016
More »
Advertisement
Advertisement